Long read sequencing enhances pathogenic and novel variation discovery in patients with rare diseases | LongRead Sequencing wiki

Source

PDF: raw/sources/sinha_2025_long_read_sequencing_enhances_pathogenic.pdf
Status: deep ingested on 2026-04-07
Scope: clinical long-read WGS workflow that unifies small variants, structural variants, phasing, and methylation in rare disease diagnostics

Samples: positive-control set of 76 cases, independent methylation-validation set of 57, and 51 previously short-read-negative rare disease patients
Platform: Oxford Nanopore whole-genome sequencing with an in-house funnel-down filtering and methylation-aware analysis pipeline
Aim: test whether one long-read workflow can recover pathogenic genomic and epigenomic variation and improve diagnosis in unsolved rare disease cases

This paper argues most directly for long-read WGS as a unified clinical platform.
The study reports detection of all known pathogenic SNV, SV, and methylation variants in its positive controls, then shows additional diagnoses in 10% of previously negative cases.
It is especially important because it combines variant detection, phasing, copy number analysis, and methylation-aware interpretation in one workflow.

The funnel-down workflow detected all pathogenic single-nucleotide, structural, and methylation variants in the positive-control cohorts used for validation.
In the 51 previously negative patients, the approach produced additional diagnoses in 10% of cases.
The paper includes examples where long reads clarify compound heterozygosity, identify pathogenic deletions, and use methylation at the SMA locus as a diagnostic signal.
Large raw callsets were reduced aggressively by filtering, showing that the bottleneck is not only generation of calls but clinically meaningful prioritization.

One of the strongest clinical workflow papers in the corpus.
Native methylation and phasing are treated as first-class diagnostic features rather than side benefits.
Uses orthogonal validation and concrete solved-case examples, not only benchmark metrics.

The unsolved cohort is still moderate in size, so the 10% uplift should be treated as promising rather than universal.
Manual review and phenotype-aware filtering remain essential.
Some candidate events still require functional follow-up, so long-read WGS does not eliminate downstream interpretation work.

This paper is the strongest counterpoint to a narrowly targeted-use view of long-read WGS.
Together with Kobayashi, it defines an important tension in the corpus: targeted deployment versus broader unified-platform deployment.

Which parts of this workflow are robust enough for routine accredited clinical labs today?
How much of the reported uplift comes from methylation, phasing, or SV detection separately?